Cargando…
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
BACKGROUND AND AIM: Mucosal healing in inflammatory bowel disease (IBD) can be achieved by improvement of intestinal barrier protection. Activation of hypoxia-inducible factor (HIF) has been identified as a critical factor for barrier protection during mucosal insult and is linked with improvement i...
Autores principales: | Gupta, Ram, Chaudhary, Anita R, Shah, Binita N, Jadhav, Avinash V, Zambad, Shitalkumar P, Gupta, Ramesh Chandra, Deshpande, Shailesh, Chauthaiwale, Vijay, Dutt, Chaitanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908906/ https://www.ncbi.nlm.nih.gov/pubmed/24493931 http://dx.doi.org/10.2147/CEG.S51923 |
Ejemplares similares
-
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
por: Zambad, Shitalkumar P, et al.
Publicado: (2013) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Zambad, Shitalkumar P, et al.
Publicado: (2011) -
TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats
por: Mohanan, Anookh, et al.
Publicado: (2011) -
TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007) -
Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)